Paper30173305
A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.
Wong PKK and 11 others. Curr Rheumatol Rep, 2018. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy. Papers, record 30173305. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30173305
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antirheumatic Agents | Major topic |
| Arthritis, Rheumatoid | Major topic |
| Biological Products | Major topic |
| Neoplasms | Major topic |
| Practice Patterns, Physicians' | Major topic |
| Humans | |
| Quality of Life |
Source PubMed
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23238979 | Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. | Rheumatology (Oxford) | 2013 | https://conductscience.org/library/papers/23238979 | PubMed |
| 2 | 24035250 | Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. | Lancet | 2013 | https://conductscience.org/library/papers/24035250 | PubMed |
| 3 | 26755797 | Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. | Ann Rheum Dis | 2016 | https://conductscience.org/library/papers/26755797 | PubMed |
| 4 | 22241900 | The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. | Ann Rheum Dis | 2012 | https://conductscience.org/library/papers/22241900 | PubMed |
| 5 | 3207388 | Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. | Ann Rheum Dis | 1988 | https://conductscience.org/library/papers/3207388 | PubMed |
| 6 | 24498893 | Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. | Mod Rheumatol | 2014 | https://conductscience.org/library/papers/24498893 | PubMed |
| 7 | 22045767 | Spectrum of cancer risk among US solid organ transplant recipients. | JAMA | 2011 | https://conductscience.org/library/papers/22045767 | PubMed |
| 8 | 30886989 | Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study. | BMC Rheumatol | 2019 | https://conductscience.org/library/papers/30886989 | PubMed |
| 9 | 22190859 | Tumor evasion from T cell surveillance. | J Biomed Biotechnol | 2011 | https://conductscience.org/library/papers/22190859 | PubMed |
| 10 | 11054684 | Risk of malignancy among patients with rheumatic conditions. | Int J Cancer | 2000 | https://conductscience.org/library/papers/11054684 | PubMed |
| 11 | 26135703 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2015 | https://conductscience.org/library/papers/26135703 | PubMed |
| 12 | 12010788 | Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. | Blood | 2002 | https://conductscience.org/library/papers/12010788 | PubMed |
| 13 | 1103152 | An endotoxin-induced serum factor that causes necrosis of tumors. | Proc Natl Acad Sci U S A | 1975 | https://conductscience.org/library/papers/1103152 | PubMed |
| 14 | 27589729 | Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/27589729 | PubMed |
| 15 | 19054822 | Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. | Ann Rheum Dis | 2009 | https://conductscience.org/library/papers/19054822 | PubMed |
| 16 | 24012043 | Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. | Semin Arthritis Rheum | 2014 | https://conductscience.org/library/papers/24012043 | PubMed |
| 17 | 26481039 | Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study. | BMC Musculoskelet Disord | 2015 | https://conductscience.org/library/papers/26481039 | PubMed |
| 18 | 20525992 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20525992 | PubMed |
| 19 | 24387057 | Leflunomide: an immunosuppressive drug with multiple effects on T cell function. | Mod Rheumatol | 2002 | https://conductscience.org/library/papers/24387057 | PubMed |
| 20 | 27147709 | Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. | Ann Rheum Dis | 2017 | https://conductscience.org/library/papers/27147709 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39605908 | Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39605908 | PubMed |
| 37476429 | Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs? | J Rheum Dis | 2022 | https://conductscience.org/library/papers/37476429 | PubMed |
| 32207688 | 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. | Turk J Gastroenterol | 2019 | https://conductscience.org/library/papers/32207688 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30173305
GET https://conductscience.org/api/papers/v1/30173305/references?page=2